Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab. Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression. Results: After 48 weeks, 92.2% of patients (mean age 50.2 +/- 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 +/- 10.3 at baseline to 1.7 +/- 3.9 and 1.4 +/- 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks. Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission. Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.

Galluzzo, M., Caldarola, G., De Simone, C., Bernardini, N., Moretta, G., Pallotta, S., et al. (2021). Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(9), 1299-1310 [10.1080/14712598.2021.1941862].

Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy

Galluzzo M.;Botti E.;Campione E.;Bianchi L.;
2021-01-01

Abstract

Background: Information is limited from real-life studies evaluating the efficacy and safety of brodalumab. Research design and methods: In this real-life study, we retrospectively examined a database of 90 patients with moderate-to-severe psoriasis treated with brodalumab (210 mg, s.c.) and followed for 1 year. Disease severity and treatment response were assessed by the Psoriasis Area and Severity Index (PASI) at baseline and after 4, 12, 24, 36, and 48 weeks. Predictors of a PASI response were evaluated by logistic regression. Results: After 48 weeks, 92.2% of patients (mean age 50.2 +/- 15 years) treated with brodalumab achieved a PASI score of <3. PASI score decreased from 17.4 +/- 10.3 at baseline to 1.7 +/- 3.9 and 1.4 +/- 3.7 at 12 and 24 weeks, and PASI 75, 90, and 100 response was achieved in 87.3%, 81.8%, and 72.7% of patients, respectively, at 48 weeks. Univariate regression revealed that previous exposure to anti-IL17A treatment was associated with poorer PASI response between 36 and 48 weeks. In difficult-to-treat cases previously having failed with other biologics, brodalumab significantly improved outcome, leading to complete remission. Conclusion: Brodalumab was observed to be effective and safe in patients with moderate-to-severe chronic psoriasis in a real-world setting.
2021
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/35 - MALATTIE CUTANEE E VENEREE
English
Anti-il17a
PASIpsoriasis
brodalumab
erythroderma
plaque psoriasis
pustular
real-life
Galluzzo, M., Caldarola, G., De Simone, C., Bernardini, N., Moretta, G., Pallotta, S., et al. (2021). Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. EXPERT OPINION ON BIOLOGICAL THERAPY, 21(9), 1299-1310 [10.1080/14712598.2021.1941862].
Galluzzo, M; Caldarola, G; De Simone, C; Bernardini, N; Moretta, G; Pallotta, S; Botti, E; Campione, E; Pirro, F; Potenza, C; Bianchi, L; Peris, K...espandi
Articolo su rivista
File in questo prodotto:
File Dimensione Formato  
66 Galluzzo - Use of brodalumab for the treatment of chronic plaque psoriasis a one year real life study in the Lazio region Italy.pdf

accesso aperto

Tipologia: Versione Editoriale (PDF)
Licenza: Copyright dell'editore
Dimensione 6.02 MB
Formato Adobe PDF
6.02 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/284060
Citazioni
  • ???jsp.display-item.citation.pmc??? 5
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 21
social impact